Another pharmacological class with high potential in the treatment of resistant hypertension to reduce BP values and outcomes, particularly HF, is represented by glyphozines (or Sodium-Glucose Cotransporter 2 Inhibitors). Here, SLC5A2 is linked to hydrops fetalis.